Brainomix, an Oxford-based leading AI-powered medtech solutions company, is expanding its presence in the US with the introduction of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.
This platform, known for its success in Europe, aims to assist clinicians in making informed decisions throughout the stroke pathway, from simple to advanced imaging.
The Brainomix 360 platform utilises cutting-edge AI algorithms for real-time interpretation of brain scans, supporting treatment decisions and transfers for stroke patients.
The recent launch featured an exhibition at the Society of Vascular and Interventional Neurology (SVIN) Conference in Miami, where Dr. Waleed Brinjikji from the Mayo Clinic shared his positive experience with the platform.
“We have been collaborating with the Brainomix team around numerous research projects over the past couple of years, including a recent study that validated the performance of their e-ASPECTS module,” noted Dr Brinjikji.
“The results showed that the accuracy of ASPECTS scoring by physicians improved across disciplines and levels of experience, which makes the e-ASPECTS module a powerful tool for clinicians across the US who are managing stroke patients.”
Dr Michalis Papadakis, co-founder and CEO of Brainomix, said: “We are delighted to have the opportunity to introduce our Brainomix 360 platform to more and more US stroke networks, and to showcase the extensive validation of our technology, a good portion of which was conducted in the US at such institutions as the Mayo Clinic, Emory University, Mount Sinai in New York, and UCLA.”
The FDA clearances include modules like e-CTP and e-MRI, aiding thrombolysis and thrombectomy decisions, especially for late-window patients i.e., those who present to hospital more than 6 to 12 hours after the onset of stroke.
Additionally, new tools, Triage LVO and Triage ICH, provide real-time alerts for suspected bleeds or large vessel occlusions, and is crucial in determining a patient’s eligibility for mechanical thrombectomy.
Brainomix, a spin-out from the University of Oxford, brings a legacy of scientific excellence. With a strong presence in the UK and Europe, the company is now expanding its operations in the US, focusing on introducing its innovative products to various hospital networks.
The success of Brainomix’s AI stroke software is evidenced by its deployment in over 30 countries and validation in more than 60 publications, showcasing improved treatment times and patient outcomes.